Diabetes mellitus in stable chronic heart failure and the combination with humoral activation, their association, and prediction of 2-year adverse outcomes. Data from the FAR NHL registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F24%3A00080372" target="_blank" >RIV/00159816:_____/24:00080372 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/24:00137178 RIV/00216208:11130/24:10484828 RIV/65269705:_____/24:00080372 RIV/00064203:_____/24:10484828 RIV/00023884:_____/24:00010004

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1111/1753-0407.13605" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1111/1753-0407.13605</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/1753-0407.13605" target="_blank" >10.1111/1753-0407.13605</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Diabetes mellitus in stable chronic heart failure and the combination with humoral activation, their association, and prediction of 2-year adverse outcomes. Data from the FAR NHL registry

Popis výsledku v původním jazyce

Background/Aim: The study aims to describe the role of diabetes in patients with heart failure. Methods: In all, 1052 chronic heart failure patients were included in the FARmacology and NeuroHumoral Activation (FAR NHL) multicenter prospective registry. They had ejection fraction below 50% and were on stable medication for at least 1 month. Results: More than one-third (38.9%) of the patients had diabetes mellitus (DM). Diabetic patients (N N = 409) were older (median 67 vs. 64, p &lt; 0.001), had higher body mass index (BMI) (30 vs. 28 kg/m(2), p &lt; 0.001), much more frequently had ischemic heart disease (71 vs. 47%, p &lt; 0.001), hypertension (80 vs. 67%, p &lt; 0.001), dyslipidemia (89 vs. 69%, p &lt; 0.001), worse renal function (estimated glomerular filtration rate [eGFR] median 63 vs. 73 mL/min/ 1.73 m(2), p &lt; 0.001), and higher N-terminal pro-brain natriuretic peptide (NTproBNP) (median 681 vs. 463 pg/mL, p = 0.003). All-cause death, left ventricle assist device implantation, and orthotopic heart transplantation were set as the combined primary end point, which was present in 15.5% (163 patients) within the 2-year follow-up. In the 2-year follow-up, 81.0% of patients with diabetes survived without a primary end point, while 85.4% of the patients without diabetes survived, the difference being on the verge of statistical significance (p = 0.089). DM is a statistically significant predictor of NT-proBNP value in univariate analysis, but it is not an independent predictor in a multivariate analysis. When the NT-proBNP level was high, the presence of DM did not influence the prognosis. Conclusion: The combination of diabetes and NT-proBNP levels may better stratify the prognosis of patients with chronic heart failure.

Název v anglickém jazyce

Diabetes mellitus in stable chronic heart failure and the combination with humoral activation, their association, and prediction of 2-year adverse outcomes. Data from the FAR NHL registry

Popis výsledku anglicky

Background/Aim: The study aims to describe the role of diabetes in patients with heart failure. Methods: In all, 1052 chronic heart failure patients were included in the FARmacology and NeuroHumoral Activation (FAR NHL) multicenter prospective registry. They had ejection fraction below 50% and were on stable medication for at least 1 month. Results: More than one-third (38.9%) of the patients had diabetes mellitus (DM). Diabetic patients (N N = 409) were older (median 67 vs. 64, p &lt; 0.001), had higher body mass index (BMI) (30 vs. 28 kg/m(2), p &lt; 0.001), much more frequently had ischemic heart disease (71 vs. 47%, p &lt; 0.001), hypertension (80 vs. 67%, p &lt; 0.001), dyslipidemia (89 vs. 69%, p &lt; 0.001), worse renal function (estimated glomerular filtration rate [eGFR] median 63 vs. 73 mL/min/ 1.73 m(2), p &lt; 0.001), and higher N-terminal pro-brain natriuretic peptide (NTproBNP) (median 681 vs. 463 pg/mL, p = 0.003). All-cause death, left ventricle assist device implantation, and orthotopic heart transplantation were set as the combined primary end point, which was present in 15.5% (163 patients) within the 2-year follow-up. In the 2-year follow-up, 81.0% of patients with diabetes survived without a primary end point, while 85.4% of the patients without diabetes survived, the difference being on the verge of statistical significance (p = 0.089). DM is a statistically significant predictor of NT-proBNP value in univariate analysis, but it is not an independent predictor in a multivariate analysis. When the NT-proBNP level was high, the presence of DM did not influence the prognosis. Conclusion: The combination of diabetes and NT-proBNP levels may better stratify the prognosis of patients with chronic heart failure.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Diabetes

ISSN

1753-0393

e-ISSN

1753-0407

Svazek periodika

16

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

"e13605"

Kód UT WoS článku

001310603500001

EID výsledku v databázi Scopus

2-s2.0-85203517235